Methods and compositions for inhibition of angiogenesis

Patent Citations (34)

Non-Patent Literature (347)

• Gutman et al. Failure of Thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Research, 1996, 16:3673-3677.Examiner
• Thomas et al. Current role of thalidomide in cancer treatment. Current Opinion in Oncology, 2000, 12:564-573.Examiner
• Alexanian et al. Primary dexamethasone treatment of multiple myeloma. Blood, 1992, vol. 80, No. 4, pp. 887-890.Examiner
• Hendler, S.S. et., “Immune Modulators Thalidomide”, The Oxygen Breakthrough 30 Days to an Illness-Free Life, William Morrow and Company, Inc., New York, pp. 217-219 (1989).Applicant
• Kenyon, et al., “The Discovery of New Inhibitors of Angiogenesis Using an Improved Mouse Corneal Neovascularization Model”, Association for Research in Vision and Opthalmology, 1995 Annual Meeting, Fort Lauderdale, Florida, No. 459-367, p. S94 (Abstract Only) (1995).Applicant
• Neubert, “Teratogenicity: Any Relationship to Carcinogenicity?”, International Agency for Research on Cancer, Cedex, France, Institute for Toxicology and Embryopharmacology, Free University of Berlin, Berlin Federal Rep. of Germany, pp. 169-178, (1979).Applicant
• Peyron, et al., “The Pharmacological Basis for the Treatment of Phodermatoses”, Biochime, vol. 68, No. 6, pp. 899-904 (1986).Applicant
• Proenca, N.G., “Thalidomide: An Eclectic Medication in Dermatology”, Rev. Paul. Med., vol. 107, No. 1, pp. 41-46. (Abstract Only) (1989).Applicant
• Robbins, K.C. “The Plasminogen-Plasmin Enzyme System”, Fibrinolysis, Hemostatsis and Thronbosis Basic Principles and Clinical Practice, 2nd Ed., Chapter 21, pp. 340-351 (1987).Applicant
• Smith, et al., “Studies on the Relationship Between the Chemical Structure and Embryotixic Activity of Thalidomide and Related Compounds”, Chemical Structure and Embryopathy, London, pp. 194-209 (1965).Applicant
• Wesolowski, et al., “Effect of Light on a Murine Model of Retinopathy of Prematurity”, Assn. for Research in Vision and Ophthalmology, Annual Meeting, Sarasota, Florida (1992).Applicant
• Algire, G. H., “Vascular Reactions of Normal and Malignant tissues In Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants”, J. Nat'l Canc. Inst., pp. 73-85 (1945).Applicant
• Allegri, A., “Confermata l'inefficacia della Talidomide Nella Terapia dei Tumori”, Gazzetta Medica Italiana, pp. 124-127 (1964).Applicant
• Ambs, S. et al., “Interactive Effects of Nitric Oxide and the p53 Tumor Suppressor Gene in Carcinogenesis and Tumor Progression”, The FASEB Journal, vol. 11, pp. 443-448 (1997).Applicant
• Apt, W. “Effect of Thalidomide on the Course of Experimental Chagas' Disease”, BOI. Chil. Parasitol, vol. 20, No. 3, pp. 84-86 (1965).Applicant
• Aronson, et al., “Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve Cultures”, Arch. Dermatol., vol. 120, No. 11, pp. 1466-1470 (1984).Applicant
• Bach, et al., “Studies on the Possible Anti-Neoplastic Effect of Thalidomide”, ACTA Pathologica ET Microbiologica scandinavica, vol. 59, pp. 491-499 (1963).Applicant
• Bach, et al., “Thalidomide in Cancer Chemotherapy”, The Lancet, vol. 1, p. 1271 (1963).Applicant
• Bahmer, F.A., “Therapie bel lymphozytischer Infiltration”, Der Hautarzt, vol. 43, p. 663 (1992).Applicant
• Balabanova, et al., “Lupus Erythermatosus Hypertrophicus et Profundus”, Z. Hautkr., vol. 67, No. 9, pp. 812-815 (1992).Applicant
• Barnes, et al., “Tumor Necrosis Factor Production in Patients with Leprosy”, Infection and Immunity, vol. 60, No. 4, pp. 1441-1446 (1992).Applicant
• Barnhill, et al., “Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various Other Conditions”, J. Am. Acad. Dermatol., vol. 7, No. 3, pp. 317-323 (1982).Applicant
• Barnhill, R. et al., “Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytres and Monocytes”, J. Am. Acad. Derm., vol. 11, No. 5, Part 1, pp. 814-819 (1984).Applicant
• Barriere, H., “Traitement par la thalidomide”, La Presse Médicale, vol. 12, No. 15, pp. 963 (1983).Applicant
• Bazzoli, et al., “The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt”, J. Embryol. Exp. Morph., vol. 41, pp. 125-135 (1977).Applicant
• Beck, Jr. et al. “Vascular Development: Cellular and Molecular Regulation”, The FASEB Journal, vol. 11, pp. 365-374 (1997).Applicant
• Beccerica, E., “L'approccio terapeutico al paziente anziano con artrite reumatoide”, Clin. Ter., vol. 122, pp. 289-298 (1987).Applicant
• Belaube, P. et al., “Should Thalidomide be Rehabilitated?”, Sem. Hop. Paris, vol. 59, No. 45, pp. 3101-3104 (1983).Applicant
• Bensinger, W.I., “Supportive Care in Marrow Transplantation”, Curr. Opin. Oncol., vol. 4, No. 4, pp. 614-623 (1992).Applicant
• Bernal, et al., “Cellular Immune Effects of Thalidomide in Actinic Prurigo”, Int'l. J. of Dermat., vol. 31, No. 8, pp. 599-600 (1992).Applicant
• Blair, R. et al., “Human Mast Cells Stimulate Vascular Tube Formation”, Journal of Clinical Investigation, vol. 99, No. 11, pp. 2691-2700 (1997).Applicant
• Blaschke, V. et al., Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere, Arzneimittel Forsch./Drug Res., vol. 29, No. II, pp. 1640-1642 (1979).Applicant
• Bonifacino, J. et al., “A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum”, Science, vol. 2, pp. 79-80 (1990).Applicant
• Bonnetblanc, et al., “Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study”, Dermatology, vol. 193, No. 4, pp. 321-323 (1996).Applicant
• Boodman, S.G., “Questions About a Popular Prenatal Test”, The Washington Post (1992).Applicant
• Bowers, et al., “Effect of Thalidomide on Orogenital Ulceration”, Br. Med. Journ., vol. 287, No. 6395, pp. 799-800 (1983).Applicant
• Braun, et al., “Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin a Coated Surfaces”, Biochem. Biophys. Res. Comm., vol. 98, No. 4, pp. 1029-1034 (1981).Applicant
• Brem, H. et al., “Interstitial Chemotherapy with Drug Polymer Implants for the Treatment of Recurrent Gliomas”, J. Neurosurg., vol. 74, pp. 441-446 (1991).Applicant
• Bressler, S. et al., “Clinicopathologic Correlation of Occult Choroidal Neovascularization in Age-Related Macular Degeneration”, Arch. Opthalmol., vol. 110, p. 827 (1992).Applicant
• Brodthagen, H., “Significant Response of Oral Aphthosis to Thalidomide Treatment”, J. Am. Acad. Dermatol., vol. 13, No. 3, p. 509 (1985).Applicant
• Brovarone, et al., “Occhio e gravidanza”, Minerva Ginecol., vol. 43, pp. 141-167 (1991).Applicant
• Browne, M.J. et al., Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells, Fibrinolysis, vol. 5, pp. 257-260 (1991).Applicant
• Bubl, et al., “Dysphagia in Dermatologic Disease”, Dysphagia, vol. 8, No. 2, pp. 85-90 (1993).Applicant
• Buckley, C. et al., “Pyoderma Gangrenosum with Severe Pharyngeal Ulceration”, J. of Royal Society of Medicine, vol. 83, pp. 590, 591 (1990).Applicant
• Buelens, I., Treatment of a Grade II Astrocytoma with Thalidomide (Phthalylglutamic Acid Imide) [Behandlung eines Astrocytoms II. Grades mit Thaliodmid (N-Phthalylglutaminsäureimid)], Arzneim.-Forsch., vol. 17, No. 5, pp. 646-648 (1967).Applicant
• Bullock, W.E., “The Clinical Significance of Erythema Nodosum”, Hosp. Pract., vol. 21, No. 3, pp. 102E-2H, 102K-2L, 102Q-2R pas (1986).Applicant
• Burger, et al., “Epidermolysis Bullosa Acquisita, a Rare Late Complication of Allogeneicbone Marrow Transplantation?”, Bone Marrow Transplant, vol. 9, No. 2, pp. 139-141 (1992).Applicant
• Burrows, N.P., “Thalidomide Modifies Disease”, Brit. Med. J., vol. 307, No. 6909, pp. 939-940 (1993).Applicant
• Buckley, C. et al., “Pyoderma Gangrenosum with Severe Pharyngeal Ulceration”, J. of the Royal Soc. of Med., vol. 83, pp. 590-591 (1990).Applicant
• Calnan, et al., “Actinic Prurigo (Hutchinson's Summer Prurigo)”, Clin. Exp. Dermatol., vol. 2, No. 4, pp. 365-372 (1977).Applicant
• Cant, J.S., “Minor Ocular Abnormalities Associated With Thalidomide”, The Lancet, p. 1134 (1966).Applicant
• Carmichael, et al., “Thalidomide: A Restricted Role”, Lancet, vol. 339, No. 8805, p. 1362 (1992).Applicant
• Cashin, C.H. et al., “Angiogenesis and Chronic Inflammation”, Agents and Actions, vol. 34, No. 3/4, pp. 332-338 (1991).Applicant
• Casini, G. et al., “Preparazione Di Uno Degli Antipodi Ottici Della 2-Ftalimmidoglutarimmide”, Il Pharmaco, Ed. Sc., vol. XIX, Fasc. 6, pp. 563-565 (1964).Applicant
• Chapon, et al., “Neuropathies Caused by Thalidomide”, Rev. Neurol., vol. 141, No. 11, pp. 719-728 (1985).Applicant
• Chaudhry, A. et al., “Effects of Prednisolone and Thalidomide on Induced Submandibular Gland tumors in Hampsters”, Canc. Res., vol. 26, No. 9, Part 1, pp. 1884-1886 (1966).Applicant
• Chen, T. et al., “Plasma Pharmocokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Healthy Male Volunteers”, The Am. Society for Pharma. and Experi. Therapeutics, vol. 17, No. 4, pp. 402-405 (1988).Applicant
• Chosidow, O, et al., “Sclerodermatous Chronic Graft-Versus-Host Disease: Analysis of Sevencases”, J. Am. Acad. Dermatol., vol. 26, No. 1, pp. 49-55 (1992).Applicant
• Claydon, et al., “Gastrointestinal Emergencies in HIV Infection”, Balliere's Clin Gastroennterol., vol. 5, No. 4, pp. 887-911 (1991).Applicant
• Clemmensen, et al., “Thalidomide Neurotoxicity”, Arch. Dermatol, vol. 120, No. 3, pp. 338-341 (1984).Applicant
• Colville-Nash, P.R. et al., “Angiogenesis and rheumatoid arthritis: Pathogenic and Therapeutic Implications”, Ann. Rheum. Dis., vol. 51, pp. 919-925 (1992).Applicant
• Congy, et al., “Plasma Zinc Levels in Elderly Patients Hospitalized in Long Stay Units. Correlations with Other Nutritional Markers, Immunological Tests and Survival”, Sem. Hop. Paris, vol. 59, No. 45, pp. 3105-3108 (1983).Applicant
• Costa, et al., “Aseptic Adenitis in a Patient with Pyoderma Gangrenosum”, Ann. Dermatol., vol. 121, No. 8, pp. 550-552 (1994) (Abstract Only).Applicant
• Crain, E. et al., “The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis”, J. of Autoimmunity, vol. 2, pp. 197-202 (1989).Applicant
• Crawford, C.L., “Letter: Thalidomide in Erythema Nodosum Leprosum”, Lancet, vol. 2, No. 839, pp. 1201-1202 (1973).Applicant
• Crawford, C.L., “Treatment of Erythema Nodosum Leprosum with Thalidomide”, Lancet, vol. 2, No. 828, pp. 567-568 (1973).Applicant
• Crawford, C.L., “Use of Thalidomide in Leprosy [letter; comment]”, BMJ, vol. 302, No. 6729, pp. 1603-1604 (1991).Applicant
• Crum, et al., “A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment”, Science, vol. 230, pp. 1375-1378 (1985).Applicant
• Current Bibliographics in Medicine, “Thalidomide: Potential Benefits and Risks”, National Inst. Health, National Library of Medicine, pp. 1-72 (Jan. 1963-Jul. 1997).Applicant
• Dark, et al., “Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature”, Cancer Research, vol. 37, pp. 1829-1834 (1997).Applicant
• David-Bajar, K.M., “Subacute Cutaneous Lupus Erythematosus”, J. Invest. Dermatol. vol. 100, No. 1, pp. 2s-8s (1993).Applicant
• D'Amato, R. J. et al., “Thalidomide is an Inhibitor of Angiogenesis”, Proc. Natl. Acad. Sci., vol. 91, pp. 4082-4085 (1994).Applicant
• D'Amato, et al., “Angiogenesis Inhibition in Age-Related Macular Degeneration”, Opthalmology, vol. 102, No. 9, pp. 1261-1262 (1995).Applicant
• D'Amato, et al., “Microscopic Analysis of Retinal-Vessels Utilizing Fluorescein-Labeled High-Molecular-Weight Dextrans”, Invest. Opthamol. & Visual Science, vol. 33, No. 4, p. 1082 (1992).Applicant
• De, A.U. et al., “Possible Antineoplastic Agents I”, J. of Pharma. Sci., vol. 64, No. 2, pp. 262-266 (1975).Applicant
• De Cock, K., “Treatment of Ulcerative Colitis”, Brit. Med. J., vol. 1, pp. 1356 (1979).Applicant
• DeKlerk, et al., “New Methods of Treatment for Renal Allotransplants Using the Baboon as a Primate Experimental Model”, J. Urol. vol. 102, No. 5, pp. 532-540 (1969).Applicant
• Dhodapkar, et al., “A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients with Multiple Myeloma”, UARK 98-003, pp. 1-15, 1995.Applicant
• Dicken, C. H., “Malignant pyoderma”, J. of the Am. Acad. of Dermatol., vol. 13, No. 6, pp. 1021-1025 (1985).Applicant
• DiPaolo, et al., “Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro”, Science, vol. 144, pp. 1583 (1964).Applicant
• DiPaolo, “Effect of Thalidomide on a Variety of Transplantable Tumors”, Cancer Chemo. Reports, vol. 29, pp. 99-102 (1963).Applicant
• DiPaolo, “In Vitro Test Systems for Cancer Chemotherapy. II. Correlation of In Vitro Inhibition of Dehydrogenase and Growth with In Vivo Inhibition of Ehrlich Ascites Tumor”, P.S.E.B.M. , vol. 114, pp. 384-387 (1963).Applicant
• DiPaolo et al., “Teratogenesis-oncogenesis: A Study of Possible Relationships”, Arch. Path., vol. 81, pp. 3-23 (1966).Applicant
• Dorveaux, et al., “Le Traitement Actuell du Lupus Erythemateux Chronique”, Le Concours Med. vol. 106, No. 31, pp. 2957-2961 (1984).Applicant
• Doutre, et al., “Pyoderma Gangrenosum and Hemopathies. A propos of 2 Cases”, Nouv Rev Fr Hematol, vol. 29, No. 4, pp. 251-254 (1987).Applicant
• Dunn, et al., “Bone Marrow Transplantation and Cataract Development”, Arch. Ophthalmol. vol. 111, No. 10, pp. 1367-1373 (1993).Applicant
• (Editorial) “Thalidomide in Dermatology and Leprosy”, Lancet, vol. 2, No. 8446, pp. 80-81 (1985).Applicant
• (Editorial) “Thalidomide Tested for Treatment of AIDS”, U.S. Pharm., vol. 18, No. 8, p. 14 (1993).Applicant
• Eger, K. et al., “Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide”, Arzheim. Forsch/Drug Res., vol. 40 (II), No. 10, pp. 1073-1075 (1990).Applicant
• Ehrlich, G.E., “Behcet's Disease: Current Concepts”, Comprehensive Therapy, vol. 15, No. 1, pp. 27-30 (1989).Applicant
• Elia, et al., “Giant Esophageal Ulcer Treated with Steroids in AIDS Patient(2)”, J. Acquired Immune Defic. Syndr., vol. 5, No. 8, pp. 848-849 (1992).Applicant
• Eisenbud, L. et al., “Recurrent Aphthous Stomatitis of the Behcet's Type: Successful Treatment with Thalidomide”, Oral Surgery, Oral Medicine, Oral Pathology, vol. 64, No. 3, pp. 289-292 (1987).Applicant
• Eravelly, J. et al., “Thalidomide in Weber-Christian Disease”, The Lancet, vol. 1, No. 8005, p. 251 (1977).Applicant
• Eriksson, et al., “Drug Exposure and Flow Cytometry Anaylses in a Thalidomide Treatment Schedule that Prolongs Rat Cardiac Graft Survival”, Transplant Proc., vol. 24, No. 6, pp. 2560-2561 (1992).Applicant
• Eriksson, S. O. et al., “Synthesis and Alkaline Hydrolysis of Some N-substituted Phthalimides”, Acta Pharm. Suecica, vol. 10, pp. 63-74 (1973).Applicant
• Fabro, S. et al., “The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its Metabolites”, Brit. J. Pharmacol., vol. 25, pp. 352-362 (1965).Applicant
• Fabro, S. et al., “Teratogenic Activity of Thalidomide and Related Compounds”, Life Sci., vol. 3, pp. 987-992 (1964).Applicant
• Fabro, S. M.D., “Biochemical Basis of Thalidomide Teratogenicity”, The Biochemical Basis of Chemical Teratogenesis, Chapter 5, pp. 159-178 (1981).Applicant
• Fajardo, et al., “Dual Role of Tumor Necrosis Factor-α in Angiogenesis”, Am. J. Pathol., vol. 140, No. 3, pp. 539-544 (1992).Applicant
• Faure, et al., “PMN Leukocytes Chemotaxis: Inhibition by Thalidomide”, Pathol. Biol. (Paris), vol. 29, No. 10, pp. 601-604 (1981).Applicant
• Faure, et al., “Inhibition of PMN Leukocytes Chemotaxis by Thalidomide”, Arch. Dermatol. Res., vol. 269, No. 3, pp. 275-280 (1980).Applicant
• Fazal, N. et al., “Effect of Blocking TNF-α on Intracellular BCG (Bacillus Calmette Guerin) Growth in Human Monocyte-Derived Macrophages”, FEMS Microbiology Immunology, vol. 105, pp. 337-346 (1992).Applicant
• Fickentscher, K. et al., “Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides”, Mol. Pharmacol., vol. 13, pp. 133-141 (1977).Applicant
• Field, E. O. et al., “Effect of Thalidomide on Splenomegaly (GVH Reaction) in the Chick Embryo. Treatment of Donor Cells Only”, Nature, vol. 211, No. 5055, pp. 1309-1310 (1966).Applicant
• Flohe, L. et al., “Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis”, Arzneimitte/Forschung (Germany West), vol. 31, No. 2, pp. 315-320 (1981).Applicant
• Folkman, J. et al., “Angiogenesis”, J. Biol. Chem., vol. 267, No. 16, pp. 10931-10934 (1992).Applicant
• Folkman, J. et al., “Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone”, Science, vol. 221, pp. 719-725 (1983).Applicant
• Folkman, J. et al., “Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia”, Nature, vol. 339, pp. 58-61 (1989).Applicant
• Folkman, J. et al., “Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy material in Rabbit Thyroid and Canine Intestinal Segment”, Anals of Surgery, pp. 491-502 (1966).Applicant
• Folkman, J., “Tumor Angiogenesis: Therapeutic Implications”, The New England J. of Med., vol. 285, No. 21, pp. 1182-1186, (1971).Applicant
• Folkman, J., “Angiogenesis and Its Inhibitors”, Important Advances in Oncology, J.B. Lippincott H. Company, pp. 42-62 (1985).Applicant
• Folkman, J., “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease”, Nature Medicine, vol. 1, No. 1, pp. 27-30 (1995).Applicant
• Folkman, J., “What is the Evidence that Tumors are Angiogenesis Dependent?”, J. Naat' Cancer Inst., vol. 82, No. 1, (1990).Applicant
• Francois, J., “Embryological Pigment Epithelial Dystrophies”, Opthalmologica, vol. 172, pp. 417-433 (1976).Applicant
• Fuller, et al., “Thalidomide, Peripheral Neuropathy and AIDS”, Int. J. STD AIDS, vol. 2, No. 5, pp. 369-370 (1991).Applicant
• Furner,, B.B., “Treatment of Subacute Cutaneous Lupus Erythematosus”, Int. J. Dermatol., vol. 29, No. 8, pp. 542-547 (1990).Applicant
• Gad, et al., “Thalidomide Induces Imbalances in T-Lymphocyte Sub-Populations in the Circulating Blood of Healthy Males”, Lepr. Rev. , vol. 56, No. 1, pp. 35-39 (1985).Applicant
• Gaetani, M., “Study Sull' Attivita Antitumorale Della Talidomide”, Giornale Italiano diu Chemioterapia, pp. 83-86, 1994.Applicant
• Gehanno, et al., “Mouth and Pharyngeal Hyperalgesic Syndromes in AIDS”, Ann. Otolarygol Chir. Cervicofac, vol. 107, No. 5, pp. 311-313 (1990).Applicant
• Genvo, et al., “Treatment of Aphthosis with Thalidomide and with Colchicine”, Dermatologica, vol. 168, No. 4, pp. 182-188 (1984).Applicant
• Geoghiou, et al., “HIV-Associated Oesophageal Ulcers Treated with Thalidomide”, Med. J. of Australia, vol. 152, pp. 382-383 (1990).Applicant
• Gershbein, “Effect of Transplanted Tumor and Various Agents on Liver Regeneration During Pregnancy”, P.S.E.B.M., vol. 126, pp. 88-92 (1967).Applicant
• Gershbein, L. L., “The Thalidomide Analog, EM 12, Enhances 1,2-dimethylhydrazine-induction of Rat Colon Adenocarcinomas”, Canc. Ltrs, vol. 60, pp. 129-133 (1991).Applicant
• Gershbein, L. L., “Effect of Various Agents on Liver Regeneration and Walker Tumor Growth in Partially Hepatectomized Rats”, Canc. Res., vol. 26, No. 9, pp. 1905-1908 (1966).Applicant
• Ghigliotti, G. et al., “Thalidomide: Treatment of Choice for Aphthous Ulcers in Patients Seropositive for Human Immunodeficiency Virus”, J. of the Am. Acad. of Dermatol., vol. 28, No. 2, Part I, pp. 271-272 (1993).Applicant
• Gimbrone, M.A. et al., “Tumor Dormancy in Vivo by Prevention of Neovasularization”, Journal of Experimental Medicine, vol. 136, pp. 261-276 (1972).Applicant
• Gimbrone, M. A. et al., “Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea”, J. Nat. Canc. Instit., vol. 52, No. 2, pp. 413-419 (1974).Applicant
• Goihman-Yahr, Mauricio et al., “Significance of Neutrophil Activation in Reactional Lepromatous Leprosy: Effects of Thalidomide in vivo and in vitro. Activation in Adjuvant Disease”, Int. Archs. Allergy Appl. Immun., vol. 57, pp. 317-332 (1978).Applicant
• Goihman-Yahr, M., et al., “Autoimmune Diseases and Thalidomide II. Adjuvant Disease, Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis of the Rat”, Int. J. Leprosy, vol. 42, No. 3, pp. 266-275 (1974).Applicant
• Gorin, I.,et al., “Thalidomide May Cure AIDS Ulcers”, Nurs. Times, vol. 86, No. 24, p. 10 (1990).Applicant
• Gorin, I., et al., “Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS”, Lancet, vol. 335, p. 1343 (1990).Applicant
• Goulden, V., et al., “Linear Prurigo Simulating Dermatitis Artefacta in Dominant Dystrophicepidermolysis Bullosa”, Br. J. Dermatol., vol. 129, No. 4, pp. 443-446 (1993).Applicant
• Grabstald, H. et al., “Clinical Experiences with Thalidomide in Patients with Cancer”, Clinical Pharmacol. and Therapeutics, vol. 6, pp. 298-302 (1965).Applicant
• Grant, D.S. et al., “Scatter Factor Induces Blood Vessel Formation in vivo”, Proc. Natl. Acad. Sci., vol. 90, pp. 1937-1941 (1993).Applicant
• Grinspan, et al., “Treatment of Aphthae with Thalidomide”, J. Am. Acad. Dermatol., vol. 20, No. 6, pp. 1060-1063 (1989).Applicant
• Grinspan, D., “Significant Response of Oral Aphthosis to Thalidomide Treatment”, Am. Acad. of Dermatol., vol. 12, No. 1, Part 1, pp. 85-90 (1985).Applicant
• Grosshans, E., et al., “Thalidomide Therapy for Inflammatory Dermatoses”, Int. J. Dermatol, vol. 23, No. 9, pp. 598-602 (1984).Applicant
• Guidetti, E., et al., “Ricerche Sull'azione Immunodepressiva Della Talidomide e del Prednisolone in Ratti Portatori Di Neoplasie Sperimentalmente Indotte”, Cancro, vol. 22, pp. 503-512 (1969).Applicant
• Günzler, V., “Thalidomide in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety Considerations”, Drug Saf, vol. 7, No. 2, pp. 116-134 (1992).Applicant
• Günzler, V., “Thalidomide—A Therapy for the Immunological Consequences of HIV Infection?”, Medical Hypotheses, vol. 30, No. 2, pp. 105-109 (1989).Applicant
• Gutiérrez-Rodriguez, O. et al., “Treatment of Refractory Rheumatoid Arthritis—The Thalidomide Experience”, The J. of Rheumatology, vol. 16, No. 2, pp. 158-163 (1989).Applicant
• Gutiérrez-Rodriguez, O. et al., “Thalidomide A Promising New Treatment for Rheumatoid Arthritis”, Arthritis and Rheumatism, vol. 27, No. 10, pp. 1118-1121 (1984).Applicant
• Haffner, M.E. M.D., “Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases”, Food and Drug Law Journal, vol. 48, pp. 205-211 (1992).Applicant
• Hamza, M. M.D., “Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide”, Clinical and Experimental Rheumatology, vol. 8, No. 4, p. 427 (1990).Applicant
• Hamza, M.H., “Treatment of Behcet's Disease with Thalidomide”, Clinical Rheumatol., vol. 5, No. 3, pp. 365-371 (1986).Applicant
• Handley, J. et al., “Chronic Bullous Disease of Childhood and Ulcerative Colitis”, Pediatric Dermatol., vol. 10, No. 3, pp. 256-258, (1993).Applicant
• Handley, J. et al., “Chronic Bullous Disease of Childhood and Ulcerative Colitis”, Brit. J. of Dermatol., vol. 127, Supp. 40, pp. 67-68 (1992).Applicant
• Harindra, et al., “Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)”, Arch. Intern. Med., vol. 152, No. 9, p. 1924 (1992).Applicant
• Harris, A., “Antiangiogenesis for Cancer Therapy”, Lancet, vol. 349 (Suppl. II), pp. 13-15 (1997).Applicant
• Hasper, M.F., “Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients”, Arch. Dermatol, vol. 19, No. 10, pp. 812-815 (1983).Applicant
• Hasper, M.F., et al., “Thalidomide in the Treatment of Chronic Discoid Lupus”, Acta. Derm. Venereol, vol. 62, No. 4, pp. 321-324 (1982).Applicant
• Hastings, R.C., et al., “Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum”, Clin. Pharmacol. Ther., vol. 11, No. 4, pp. 481-487 (1970).Applicant
• Hatfill, S.J. et al., “Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites”, Leukemia Res., vol. 15, No. 2/3, pp. 129-136 (1991).Applicant
• Hayashi, S. et al., “A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines”, J. Clin. Invest., vol. 99, No. 11, pp. 2581-2587 (1997).Applicant
• Heaton, et al., “Graft-versus-Host Disease Following Liver Transplantation”, J. R. Soc. Med., vol. 85, No. 6, pp. 313-314 (1992).Applicant
• Hellman, K. et al., “Prolongation of Skin Homograft Survival by Thalidomide”, Brit. Med. J., vol. 2, pp. 687-689 (1965).Applicant
• Helm, F. -Ch. et al., “Comparative Teratological Investigation of Compounds Structurally and Pharmacologically Related to Thalidomide”, Arzneim.-Forsch./Drug Res., vol. 31 (I), No. 6, pp. 941-949 (1981).Applicant
• Hendler, S. S. et al., “Thalidomide for Autoimmune Disease”, Medical Hypotheses, vol. 10, pp. 437-443 (1983).Applicant
• Heney, D. et al., “Thalidomide Treatment for Chronic Graft-Versus-Host Disease”, Brit. J. of Haematol. vol. 78, pp. 23-27 (1991).Applicant
• Heney, D., et al., “Thalidomide in the Treatment of Graft-versus-Host Disease”, Biomed. Pharmacother, vol. 44, No. 4, pp. 199-204 (1990).Applicant
• Heney, D., et al., “Thalidomide for Chronic Graft-versus-Host Disease in Children”, Lancet, vol. 2, No. 8623, p. 1317 (1988).Applicant
• Hojyo, et al., “Actinic Prurigo (9)”, Int. J. Dermatol., vol. 31, No. 5, pp. 372-373 (1992).Applicant
• Holm, et al., “Chronic Cutaneous Lupus Erythematosus Treated with Thalidomide”, Arch. Dermatol., vol. 129, No. 12, pp. 1548-1550 (1993).Applicant
• Hori, A. et al., “Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor”, Canc. Res., vol. 51, pp. 6180-6184 (1991).Applicant
• Hu, D.E., “Inhibition of Angiogenesis in Rats by IL-1 Receptor Antagonist and Selected Cytokine Antibodies”, Inflammation, vol. 18, pp. 45-58 (1994).Applicant
• Hu, J. et al., “A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells”, The FASEB Journal, vol. 11, pp. 498-504 (1997).Applicant
• Ingber, D. et al., “Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumor Growth”, Ltrs. to Nat., vol. 348, pp. 555-557 (1990).Applicant
• Ingber, D., “Drug News and Trial Developments”, AIDS Patient Care, vol. 6, No. 6, p. 288 (1992).Applicant
• Randall, T., “Thalidomide's Back in the News, but in more Favorable Circumstances”, JAMA, vol. 263, No. 11, pp. 1467-1468 (1990).Applicant
• Jacobson, J. et al., “Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection”, The New England Journal of Medicine, vol. 336, No. 21, pp. 1487-1493 (1997).Applicant
• Jacobson, et al., “The Diagnosis and Treatment of Leprosy”, South Med.. J., vol. 69, No. 8, pp. 979-985 (1976).Applicant
• Jager, et al., “Clinical Observations in the Treatment of Leprosy Reaction with Cyclic Imides”, Int. J. Lepr. Other Mycobact Dis., vol. 39, No. 2, p. 589 (1971).Applicant
• Jeltsch, M. et al., “Hypeplasia of Lymphatic Vessels in VEGF-C Transgenic Mice”, Science, vol. 276, pp. 1423-1426 (1997).Applicant
• Jenkins, et al., “Thalidomide, Orogenital Ulcers, and Risk of Teratogenicity”, The Lancet, vol. 1, No. 8417-18, p. 511 (1985).Applicant
• Jenkins, et al., “Thalidomide in Severe Orogenital Ulceration”, The Lancet, vol. 2, No. 8417-18, pp. 1424-1426 (1984).Applicant
• Jennings, et al., “Effect of Actinomycin D on the Production of Acute Phase Protein in the Rabbit”, Experienta, vol. 25, pp. 305-306 (1969).Applicant
• Jew, et al., “Thalidomide in Erythema Nodosum Leprosum”, DICP, vol. 24, No. 5, pp. 482-483 (1990).Applicant
• Johnke, et al., “Thalidomide Treatment of Prurigo Nodularis”, Ugeskr Laeger, vol. 155, No. 38, pp. 3028-3030 (1993) (Abstract Only).Applicant
• Jönsson, N., “Chemical Structure and Teratogenic Propeties IV. An Outline of a Chemical Hypothesis for the Teratogenic Action of Thalidomide”, Acia Pharm. Succica, vol. 9, pp. 543-562 (1972).Applicant
• Jönsson, N., “Chemical Structure and Teratogenic Properties I. Synthesis and Teratogenic Activity in Rabbits of some Derivatives of Phthalidmide, Isoindoine-1-one, 1.2-Benzisothiazoline-3-one-1, 1-Dioxide and 4(3II)-Quinazolinone”, Acia Pharm Succica, vol. 9, pp. 431-436 (1972).Applicant
• Jönsson, N., “Chemical Structure and Teratogenic Properties III a Review of Available Data on Structure-Activity Relationships and Mechanism of Action of Thalidomide Analogues”, Acia Pharm. Succia, vol. 9, pp. 521-542 (1972).Applicant
• Jorizzo, et al., “Thalidomide Effects in Behcet's Syndrome and Pustular Vasculitis”, Arch. Intern. Med., vol. 146, No. 5, pp. 878-881 (1986).Applicant
• Juret, et al., “Absence d'effet Carcino-Frénateur du Talidomide vis-á-vis de deux Tumerus Greffées”, Société de Biologie, vol. 23, pp. 246-249 (1963).Applicant
• Kaitin, K.I., “Graft-versus-Host Disease”, N. Engl. J. Med., vol. 325, No. 5, pp. 357-358 (1991).Applicant
• Kaplan, G. et al., “TNFα regulation of HIV1: Biology and Therapy”, Res. in Immunology, vol. 145, No. 8-9, pp. 685-690 (1994).Applicant
• Katsuta, et al., “Carcinogenesis in Tissue Culture. 3. Effects of the Second Treatments on DAB-Induced Proliferating Liver Cells of Normal Rats in Culture”, Jpn. J. Exp. Med., vol. 35, No. 4, pp. 231-248 (1965).Applicant
• Keenan, R.J. et al., “Immunosuppressive Properties of Thalidomide”, Transplantation, vol. 52, No. 5, pp. 908-910 (1991).Applicant
• Kim, K. J. et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth in vivo”, Ltrs. to Nat., vol. 362, pp. 841-844 (1993).Applicant
• Kitamoto, Y. et al., “Vascular Endothelial Growth Factor is an Essential Molecule for Mouse Kidney Development: Glomerulogenesis and Nephrogenesis”, J. Clin.. Invest., vol. 99, No. 10, pp. 2351-2357 (1997).Applicant
• Klug, S. et al., “Embryotoxic Effects of Thalidomide Derivatives in the Non-Human Primate Callithrix Jacchus”, Arch . Toxicol. vol. 68, pp. 203-205 (1994).Applicant
• Knighton, D. et al., “Avascular and Vascular Phases of Tumor Growth in the Chick Embryo”, Br. J. Canc., vol. 35, pp. 347-356 (1977).Applicant
• Knop, et al., “Thalidomide in the Treatment of Sixty Cases of Chronic Discoid Lupus Erythematosus”, Br. J. Dermatol, vol. 108, No. 4, pp. 461-466 (1983).Applicant
• Koch, H.P. et al., “4 Thalidomide and Congeners as Anti-inflammatory Agents”, Progress in Medicinal Chemistry, vol. 22, pp. 166-242 (1985).Applicant
• Korn, et al., “The Second International Workshop on Scleroderma Research”, Matrix, vol. 13, No. 5, pp. 427-429 (1993).Applicant
• Kroger, et al., “Synergistic Effects of Thalidomide and Poly (ADP-ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice”, Inflammation, vol. 20, No. 2, pp. 203-215 (1996).Applicant
• Kundu, et al., “Prurigo Nodularis in an HIV Positive Man (2)”, Genitourinary Medicine, vol. 71, No. 2, pp. 129-130 (1995).Applicant
• Kürkcüoglu, N. et al., “Thalidomide in the treatment of Recurrent Necrotic Mucocutaneous Aphthae”, Brit. J. of Dermatol., vol. 112, No. 5, pp. 632 (1985).Applicant
• Lane, et al., “Treatment of Actinic Prurigo with Intermittent Short-Course Topical 0.05% Clobetasol 17-Propionate. A Preliminary Report”, Arch. Dermatol, vol. 126, No. 9, pp. 1211-1213 (1990).Applicant
• Languillon, J., “The Effects of Thalidomide on Leprosy Reaction”, Int. J. Lepr. Other Mycobact. Dis., vol. 39, No. 2, pp. 590-592 (1971).Applicant
• Larsson, H., “Treatment of Severe Colitis in Behcet's Syndrome with Thalidomide (CG-217)”, J. of Intern. Med., vol. 228, pp. 405-407 (1990).Applicant
• Ledo, E., “Photodermatosis. Part I: Photobiology, Photoimmunology, and Idiopathicphotodermatoses”, Int. J. Dermatol., vol. 32, No. 6, pp. 387-396 (1993).Applicant
• Lehner, T., et al., “Thalidomide, Orogenital Ulcers, and the Risk of Teratogenesis”, The Lancet, vol. 8423, pp. 288-289 (1985).Applicant
• Lenicque, “Action of Thalidomide on the Induction of Tentacles in Regenerating Hydra Littoralis”, Acta. Zool., pp. 127-139 (1967).Applicant
• Levy, et al., “Treatment of Erythema Nodosum Leprosum with Thalidomide”, The Lancet, vol. 2, No. 824, pp. 324-325 (1973).Applicant
• Lien, W. M. et al., “The Blood Supply of Experimental Liver Metastases. II. A microcirculatory Study of the Normal and Tumor Vessels of the Liver with the Use of Perfused Silicone Rubber”, Surgery, vol. 68, No. 2, pp. 334-340 (1970).Applicant
• Lo, et al., “Treatment of Discoid Lupus Erythematosus”, Int. J. Dermatol., vol. 28, No. 8, pp. 497-507 (1989).Applicant
• Londono, F., “Thalidomide in the Treatment of Actinic Prurigo”, Int. J. Dermatol., vol. 12, No. 5, pp. 326-328 (1973).Applicant
• Lovell, et al., “Thalidomide in Actinic Prurigo”, Br. J. Dermatol, vol. 108, No. 4, pp. 467-471 (1983).Applicant
• Lopez, J. et al., “Thalidomide as Therapy for Intestinal Chronic GVHD”, Bone Marrow Transplantation, vol. 11, No. 3, pp. 251-252 (1993).Applicant
• Louzir, B. et al., “Erythroleucemie chez un patient ayant une maladie de Behcet et traite au long cours par thalidomide”, Annales de Medecine Interne, vol. 143, pp. 479-480 (1992).Applicant
• Lueprasitsakul, W. et al., “Effect of Thalidomide on the Incidence of Iodine-Induced and Spontaneous Lymphocytic Thyroiditis and Spontaneous Diabetes Mellitus in the BB/Wor Rat”, Acta Endocrino Logica, vol. 123, pp. 79-83 (1990).Applicant
• Lüers, H., “Failure of Mutagenic Action of Thalidomide in Drosophila”, The Lancet, vol. II, No. 7258, p. 1332 (1962).Applicant
• Magana-Garcia, M., “Antimalarials for Children”, J. Am. Acad. Dermatol, vol. 30, No. 3, p. 510 (1994).Applicant
• Maione, T. E. et al., “Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides”, Science, vol. 2, pp. 77-78 (1990).Applicant
• Makonkawkeyoon, S. et al., “Thalidomide Inhibits the Replication of Human Immunodeficiency virus type 1”, Proc. Natl. Acad. Sci., vol. 90, pp. 5974-5978 (1993).Applicant
• Marin-Padilla, M. et al. “Thalidomide Induced alterations in the Blastocyst and Placenta of the Armadillo, Dasypus Novemcinctus Mexicanus, Including a Choriocarcinoma”, The Am. J. of Pathol., vol. 43, No. 6, pp. 999-1016 (1963).Applicant
• Mascaro, et al., “Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis”, Arch. Dermt., vol. 115, pp. 636-637 (1979).Applicant
• Matsubara, et al., “Inhibition of Human Endothelial Cell Proliferation by Gold Compounds”, J. Clin. Invest., vol. 79, pp. 1440-1446 (1987).Applicant
• Matsuyama, T. et al., “Cytokines and HIV Infection: is AIDS a Tumor Necrosis Factor Disease?”, AIDS, vol. 5, No. 12, pp. 1405-1417 (1991).Applicant
• Mauád, “Melhoras Clínicas Obtidas em Doentes Cancerosos Avançados com Tratamento Pela Talidomida Associada a Hormônios”, Anais Paulistas Medicina e Cirurgia, pp. 15-39 (1963).Applicant
• Maurice, et al., “The Effect of Thalidomide on Arachidonic Acid Metabolism in Human Polymorphonuclear Leukocytes and Platelets”, Br. J. Dermatol., vol. 115, No. 6, pp. 677-680 (1986).Applicant
• McCarthy, et al., “Thalidomide for the Therapy of Graft-versus-Host Disease Following Allogeneic Bone Marrow Transplantation”, Biomed. Pharmacother, vol. 43, No. 9, pp. 693-697 (1989).Applicant
• McKenna, et al., “Linear IgA Disease, Oral Ulceration and Crohn's Disease”, Br. J. Dermatol, vol. 127, pp. 67-68 (1992).Applicant
• Meza, D. et al., “Managing the Gastrointestinal Complications of AIDS”, Drug Therapy, vol. 23, No. 11, pp. 74-83 (1993).Applicant
• Miller, et al., “Zusammentreffen Einer Thalidomid-Induzierten Fehlbildung mit Einem Malignen Lymphom Hohen Malignitätsgrades”, Monatsschr. Kinderheilkd., vol. 128, pp. 27-29 (1980).Applicant
• Miller, et al., “Treatment of Chronic Erythema Nodosum Leprosum with Cyclosporine A Produces Clinical and Immunohistologic Remission”, Int. J. Lepr. Other Mycobact. Dis., vol. 55, No. 3, pp. 441-449 (1987(.Applicant
• Misery, L. et al., “Remission of Langerhans Cell Histiocytosis with Thalidomide Treatment”, Clinical and Experimental Dermatol., vol. 18, No. 5, p. 487 (1993).Applicant
• Miura, M. et al., “Potentiating Effect of Thalidomide on Methylcholanthrene Oncogenesis in Mice”, Experieentia, vol. 26, Fasc. 3, pp. 305-306 (1970).Applicant
• Miyachi, Y., “A Possible Mechanism of Action of Thalidomide on Rheumatoid Arthritis”, Arthritis and Rheuma., vol. 28, No. 7, p. 836 (1985).Applicant
• Miyachi, et al., “Effects of Thalidomide on the Generation of Oxygen Intermediates by Zymosan-Stimulated Normal Polymorphonuclear Leukocytes”, Arch. Dermatol. Res., vol. 274, Nos. 3-4, pp. 363-367 (1982).Applicant
• Mohri, et al., “Negative Effect of Thalidomide and Relative Substances on the Growth of HeLa Cells”, Chem. Pharm. Bull., vol. 16, pp. 2289-2292 (1968).Applicant
• Moncada, et al., “Thalidomide—Effect on T Cell Subsets as a Possible Mechanism of Action”, Int. J. Lepr. Other Mycobact. Dis., vol. 53, No. 2, pp. 201-205 (1985).Applicant
• Montrucchio, et al., “Tumor Necrosis Factor α-Induced Angiogenesis Depends on In Situ Platelet-Activating Factor Biosynthesis”, J. Exp. Med, vol. 180, pp. 377-382 (1994).Applicant
• Moulin, et al., “Treatment of Jessner-Kanof Disease with Thalidomide”, Ann. Dermatol Venereol, vol. 10, No. 8, pp. 611-614 (1983).Applicant
• Mshana, et al., “Thymus-Dependent Lymphocytes in Leprosy. II. Effect of Chemotherapy on T-Lymphocyte Subpopulations”, J. Clin. Immunol., vol. 2, No. 2, pp. 69-74 (1982).Applicant
• Mückter, et al., “Thalidomide and Tumor”, Antimicrobial Agents and Chemotherapy, pp. 531-538 (1965).Applicant
• Mummery, C.L. et al., “Screening for Cytoxicity in Neuroblastoma Cells-I. Dependence of Growth Inhibition on the Presence of Serum”, Toxicology Letters, vol. 18, pp. 201-209 (1983).Applicant
• Munro, et al., “Pyoderma Gangrenosum Associated with Behcet's Syndrome-Response to Thalidomide”, Clin. Exp. Dermatol., vol. 13, No. 6, pp. 408-410 (1988).Applicant
• Muthukkaruppan, Vr. et al., “Angiogenesis in the Mouse Cornea”, Science, vol. 205, No. 28, pp. 1416-1418 (1979).Applicant
• Naafs, B. et al., “Thalidomide Therapy An Open Trial”, Intl. J. of Dermatol., vol. 24, No. 2, pp. 131-134 (1985).Applicant
• Naafs, B., Bangkok Workshop on Leprosy Research. Treatment of Reactions and Nerve Damage. Int. J. Lepr. Other Mycobact. Dis., vol. 64, No. 4, Suppl. S21-28 (1996).Applicant
• Nguyen, M. et al., “Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients”, J. of the Natl. Canc. Inst., vol. 85, No. 3, pp. 241-242 (1993).Applicant
• Nguyen, M. et al., “Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Patients with a Wide Spectrum of Cancers”, J. of the Natl. Canc. Inst., vol. 86, No. 5, pp. 356-361 (1994).Applicant
• Nicolas, J., et al., “Interferon Alfa Therapy in Severe Unresponsive Subacute Cutaneous Lupus Erythematosus”, New Engl. J. Med., vol. 321, No. 22, pp. 1550-1551 (1989).Applicant
• Nicolau, et al., “Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS”, DICP, vol. 24, No. 11, pp. 1054-1056 (1990).Applicant
• Nielsen, et al., “Thalidomide Enhances Superoxide Anion Release from Human Polymorphonuclear and Leukocytes”, Acta. Pathol. Microbiol. Immunol. Scand. [C], vol. 94, No. 6, pp. 233-237 (1986).Applicant
• Obeso, J. et al., “Methods in Laboratory Investigation A Hemangioendothelioma-Derived Cell Line: Its Use as a Model for the Study of Endothelial Cell Biology”, Laboratory Investigation, vol. 63, No. 2, pp. 259-269 (1990).Applicant
• Oikawa, T. et al., “Eponemycin, A Novel Antibiotic is a Highly Powerful Angiogenesis Inhibitor”, Biochem. and Biophy. Res. Comm., vol. 181, No. 3, pp. 1070-1077 (1991).Applicant
• Olson, et al., “Thalidomide (N-phthaloylglutamimide) in the Treatment of Advanced Cancer”, Clin. Pharmacol. Therap., vol. 6, No. 3, pp. 292-297 (1965).Applicant
• Orzalesi, M., “Il Danno Iatrogeno in Neonatologica”, Ped. Med. Chir., vol. 14, pp. 105-112 (1992).Applicant
• Ostraat, et al., “Thalidomide Prolongs Graft Survival in Rat Cardiac Transplants”, Transplant Proc., vol. 24, No. 6, pp. 2624-2625 (1992).Applicant
• Otsuka, et al., “A New Potent Angiogenesis Inhibitor, FR-118487”, J. of Microbiol. and Biotechno., vol. 1, No. 3, pp. 163-168 (1991).Applicant
• Paller, et al., “Proceedings of the Concurrent Sessions”, Pediatr. Dermatol, vol. 9, No. 4, pp. 397-406 (1992).Applicant
• Passaniti, A. et al., “Methods in Laboratory Investigation A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor”, Laboratory Investigation, vol. 67, No. 4, pp. 519-528 (1992).Applicant
• Patey, O. et al., “Thalidomide et colite ulcereuse dans la maladie de Behcet”, Gastroenterol. Clin. Biol., vol. 13, pp. 104-110 (1989).Applicant
• Pearson, et al., “Treatment of Moderately Severe Erythema Nodosum Leprosum with Thalidomide—A Double-Blind Controlled Trial”, Lepr. Rev., vol. 40, No. 2, pp. 111-116 (1969).Applicant
• Pfordte, “Ûber die Beeinflussung des Serumproperdinsystems Durch Verschiedene Arzneimittel”, Pharmazie, vol. 26, pp. 301-302 (1971).Applicant
• Phillips, et al., “Tumor Necrosis Factor Alpha (rhTNF) Fails to Stimulate Angiogenesis in the Rabbit Cornea”, Anatomical Rec., vol. 245, pp. 53-56 (1996).Applicant
• Powell, R.J. et al., “Investigation and Treatment of Orogenital Ulceration; studies on a Possible Mode of Action of Thalidomide”, Brit. J. of Dermatol., vol. 113, Supp. 28, pp. 141-144 (1985).Applicant
• Prigent, F. et al., “Sarcoidose cutanee Traitement par la Thalidomide”, La Presse Medicale, vol. 12, No. 47, p. 3007 (1983).Applicant
• Radeff, et al., “Recurrent Aphthous Ulcer in Patient Infected with Human Immunodeficiency Virus: Successful Treatment with Thalidomide”, J. Am. Acad. Dermatol, vol. 23, No. 3, Pt. 1, pp. 523-525 (1990).Applicant
• Rainsford, K.D., “Disease-Modifying Antirheumatic and Immunoregulatory Agents”, Bailliere's Clinical Rheumatology, vol. 4, No. 3, pp. 405-432 (1990).Applicant
• Rajan, et al., “A Clinical Study of Thalidomide Comparing Pre-Treatment and Post-Treatment Reactional Episodes and Corticosteroid Requirements”, Lepr. India, vol. 55, No. 1, 111-116 (1983).Applicant
• Randall, T., “Investigational New Drug (US) ‘Orphan’ Trials now Use Thalidomide from two Sources”, JAMA, vol. 263, No. 11, p. 1474 (1990).Applicant
• Revuz, J., “Actualite Du Thalidomide”, Ann. Dermatol. Venereol., vol. 117, pp. 313-321 (1990).Applicant
• Revuz, J. et al, “Crossover Study of Thalidomide vs. Placebo in Severe Recurrent Aphthous Stomatitis”, Arch. Dermatol, vol. 126, pp. 923-927 (1990).Applicant
• Rhoton, A. J., “Role for Thalidomide in Primary Biliary Cirrhosis Treatment?”, Gastroenterology, vol. 105, No. 3, p. 956 (1993).Applicant
• Roe, F.J.C., “Pathology Thalidomide and Neoplasia”, Nature, vol. 200, pp. 1016-1017 (1963).Applicant
• Roe, et al., “Tumour-Incidence in Progeny of Thalidomide-Treated Mice”, British J. Cancer, pp. 331-333, (1965).Applicant
• Ruggenini, et al., “Talidomide e Tumori Sperimentali”, Cancro, vol. 20, pp. 39-55 (1967).Applicant
• Rustin, et al., “Pyoderma Gangrenosum Associated with Behcet's Disease: Treatment with Thalidomide”, J. Am. Acad. Dermatol, vol. 23, No. 5, Pt. 1, pp. 941-944 (1990).Applicant
• Ryan, et al., “Thalidomide to Treat Esophageal Ulcer in AIDS (6)”, New Engl. J. Med., vol. 327, No. 3, pp. 208-209 (1992).Applicant
• Salven, P. et al., “Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer”, Clinical Cancer Research, vol. 3, pp. 647-651 (1997).Applicant
• Sampaio, et al., “Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients”, J. Exp. Med., vol. 175, No. 6, pp. 1729-1737 (1992).Applicant
• Sampaio, et al., “Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes”, J. Exp. Med., vol. 173, No. 3, pp. 699-703 (1991).Applicant
• Santis, H.R., “Aphthous Stomatitis and its Management”, Curr. Opin. Dent, vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only).Applicant
• Santos, et al., “In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum”, Clin. Immunol. Immunopathol., vol. 67, No. 3 I, pp. 199-203 (1993).Applicant
• Sato, K. et al., “Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules”, Journal of Clinical Endocrinology and Metabolism, vol. 82, No. 6, pp. 1968-1972 (1997).Applicant
• Schweigerer, L. et al., “Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases”, European J. of Pediatric, vol. 151, pp. 472-476 (1992).Applicant
• Shannon, et al., “Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy”, Scand. J. Immunol., vol. 13, No. 6, p. 553-562 (1981).Applicant
• Shannon, et al. , “Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood”, Lepr. Rev., vol. 63, No. 1, pp. 5-11 (1992).Applicant
• Shealy, Y.F. et al., “D-and L-Thalidomide”, Chemistry and Industry, pp. 1030-1031 (1965).Applicant
• Sheehan, N.J., “Thalidomide Neurotoxicity and Rheumatoid Arthritis”, Arthritis and Rheuma., vol. 29, No. 10, p. 1296 (1986).Applicant
• Sherman, M. et al., “Thalidomide: A Twenty-Five Year Perspective”, Food Drug Cosmetic Law J., vol. 41, pp. 458-466 (1986).Applicant
• Sheskin, J., “The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide”, Int. J. Dermatol., vol. 19, No. 6, pp. 318-322 (1980).Applicant
• Sheskin, et al., “In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide”, Dermatologica, vol. 162, No. 2, pp. 86-90 (1981).Applicant
• Shi, G. et al., “Kringle Domains and Plasmin Denaturation”, Biochem. and Biophy. Res. Comm., vol. 178, No. 1, pp. 360-368 (1991).Applicant
• Sidky, Y. et al., “Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses”, Canc. Res., vol. 47, pp. 5155-5161 (1987).Applicant
• Silverman, W.A., “Medical Inflation”, Persp. Biol. Med., pp. 617-637 (1980).Applicant
• Srivastava, A. et al., “The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin Melanoma”, Am. J. Pathol., vol. 133, pp. 419-423 (1988) (abstract from Medline: Accession No. 06745734).Applicant
• Style, A., “Early Diagnosis and Treatment of Leprosy in the United States”, American Family Physician, vol. 52, No. 1, 172-178 (1995).Applicant
• Sugiura, et al., “Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors”, GANN, vol. 55, pp. 57-60 (1964).Applicant
• Swift, T.R., “Thalidomide in Erythema Nodosum Leprosum”, Lancet, vol. 2, No. 835, p. 966 (1973.Applicant
• Szydlowska, et al., “On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations”, Folia Histo. Cytochem., vol. 16, No. 3, pp. 233-240 (1978).Applicant
• Tamura, et al., “Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprodnisolone and Cyclosporine”, Transplantation, vol. 49, No. 1, p. 20-25 (1990).Applicant
• Tanaka, Y. et al., “Vascular Endothelial Growth Factor in Diabetic Retinopathy”, The Lancet, vol. 349, p. 1520 (1997).Applicant
• Taylor, S. et al., “Protamine is an Inhibitor of Angiogenesis”, Nature, vol. 297, pp. 307-312 (1982).Applicant
• Teppo, L. et al., “Thalidomide-Type Malformations and Subsequent Osteosarcoma”, The Lancet, vol. II, No. 8034, p. 405 (1977).Applicant
• “Thalidomide 20 Years On”, The Lancet, vol. II, No. 8245, pp. 510-511 (1981).Applicant
• “Thalidomide”, The Merck Index, 11th ed., p. 1458 (1989).Applicant
• Theophilus, S., “Treatment with Thalidomide in Steroid Dependency and Neuritis”, Lepr. India, vol. 52, No. 3, pp. 423-428 (1980).Applicant
• Thomas, et al., “Effect of Thalidomide on Liver Regeneration in Rat”, Indian J. Exp. Biol., vol. 10, pp. 314-315 (1972).Applicant
• Thomas, et al., “Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flavivirdis”, Indian J. Exp. Biol., vol. 10, pp. 316-317 (1972).Applicant
• Thomas, L. et al., “Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide”, Archives of Dermatol., vol. 129, pp. 1261-1264 (1993).Applicant
• Torry, R. J. et al., “Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis”, Am. J. of Reproductive Immunology, vol. 27, pp. 171-179 (1992).Applicant
• Traldi, et al., “L'impiego Dell'imide Dell'Acido N'ftalilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affeti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina”, Cancro, vol. 18, pp. 336-341 (1965).Applicant
• Trautman, J. R., “Treatment of Hansen's Disease”, Curtis, vol. 18, No. 1, 62-65 (1976).Applicant
• Van den Broek, H., “Treatment of Prurigo Nodularis with Thalidomide”, Arch. Dermatol, vol. 116, No. 5, pp. 571-572 (1980).Applicant
• Vasilescu, et al., “Cercetari Privind Actiunea Talidomidei Asupra Celulelor Cultivate in Vitro”, Cerc. Fiziol., vol. 13, No. 4, pp. 293-300 (1968).Applicant
• Verhaul, et al., “Combination Oral Antiangiogenic Therapy with Thalidomide and Sulindac Inhibits Tumor Growth in Rabbits”, Brit. J. Cancer, vol. 79, No. 1, pp. 114-118 (1999).Applicant
• Vicente, T. et al., “In Vitro Activity of Thalidomide Against Mycobacterium avium Complex”, Archives of Internal Medicine, vol. 153, p. 334 (1993).Applicant
• Villa, et al., “Antimytotic Effect of Thalidomide and its Metabolites on the Chick Embryo Blood Cells”, Haematol. Latina, vol. 6, pp. 217-221 (1963).Applicant
• Villa, et al., “Cytological Effects of Thalidomide”, The Lancet, pp. 725 (1963).Applicant
• Vladutiu, A., “Another Chance for Thalidomide?”, The Lancet, vol. I, No. 7444, pp. 981-982 (1966).Applicant
• Vogelsang, G. B. et al., “Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease”, New England J. of Med., vol. 326, pp. 1055-1059 (1992).Applicant
• Vogelsang, et al., “Therapy of Chronic Graft-v-Host Disease in a Rat Model”, Blood, vol. 74, No. 1, No. 1, pp. 507-511 (1989).Applicant
• Vogelsang, et al., “Thalidomide Induction of Bone Marrow Transplantation Tolerance”, Transplant Proc., vol. 19, No. 1, Pt. 3, pp. 2658-2661 (1987).Applicant
• Vogelsang, et al., “Treatment and Prevention of Acute Graft-versus-Host Disease with Thalidomide in a Rat Model”, Transplantation, vol. 41, No. 5, pp. 644-647 (1986).Applicant
• Vogt, B. et al., “Inhibition of Angiogenesis in Kaposi's Sarcoma by Captopril”, The Lancet, vol. 349, p. 1148 (1997).Applicant
• Waters, M.F. et al., “Treatment of Ulcerative Colitis with Thalidomide”, Brit. Med. J., vol. 1, No. 6166, pp. 792 (1979).Applicant
• Waters, M., “Use of Thalidomide in Leprosy”, BMJ, vol. 303, No. 6800, p. 470 (1991).Applicant
• Waters, M.F., “An Internally-Controlled Double Blind Trial of Thalidomide in Severe Erythema Nodosum Leprosum”, Lepro. Rev., vol. 42, No. 1, pp. 26-42 (1971).Applicant
• Weidner, J. et al., “Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma”, The New England J. of Med., vol. 324, No. 1, pp. 1-8 (1991).Applicant
• Weidner, N. et al., “Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Cancer”, Am. J. of Pathol., vol. 143, No. 2, pp. 401-409 (1993).Applicant
• Weidner, N. et al., “Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma”, J. of Nat. Canc. Inst., vol. 84, No. 24, 1875-1887 (1992).Applicant
• White, C. W. et al., “Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a”, The New England J. of Med., vol. 32, No. 18, pp. 1197-1200 (1989).Applicant
• Williams, K. M., “Enantiomers in Arthritic Disorders”, Pharmacol. & Therapeutics, vol. 46, No. 2, pp. 273-295 (1990).Applicant
• Williams, et al., “Thalidomide Hypersensitivity in AIDS”, Lancet, vol. 337, pp. 436-437 (1991).Applicant
• Winkelmann, et al., “Thalidomide Treatment of Prurigo Nodularis”, Acta. Derm. Venereol., vol. 64, No. 5, pp. 412-417 (1984).Applicant
• Wood, et al., “The Potential use of Thalidomide in the Therapy of Graft-versus-Host Disease—A Review of Clinical and Laboratory Information”, Leuk. Res. , vol. 14, No. 5, pp. 395-399 (1990).Applicant
• Woodyatt, P.B., “Thalidomide”, The Lancet, p. 750. (1962).Applicant
• Wulff, et al., “Development of Polyneuropathy During Thalidomide Therapy”, Br. J. Dermatol., vol. 112, No. 4, pp. 475-480 (1985).Applicant
• Yazici, et al., “Practical Treatment Recommendations for Pharmacotherapy of Behcet's Syndrome”, Drugs, vol. 42, No. 5, pp. 796-804 (1991).Applicant
• Yoshimura, T. et al., “Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST1) Confirms MSP as a member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3”, The J. of Biol. Chem., vol. 268, No. 21, pp. 15461-15468 (1993).Applicant
• Youle, et al., “Treatment of Resistant Aphthous Ulceration with Thalidomide in Patients Positive for HIV Antibody”, BMJ, vol. 298, No. 6671, p. 432 (1989).Applicant
• Youle, et al., “Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS”, Lancet, vol. 335, No. 8705, p. 1591 (1990).Applicant
• Yue, t. et al., “2-Methoxyestradiol, an Endogenous Estrogen Metabolite, Induces Apoptosis in Endothelial Cells and Inhibits Angiogenesis: Possible Role for Stress-Activated Protein Kinase Signaling Pathway and Fas Expression”, Molecular Pharmacology, vol. 51, pp. 951-962 (1997).Applicant
• Ziche, M. et al., “Nitric Oxide Synthase Lies Downstream from Vascular Endothelial Growth Factor-induced but Not Basic Fibroblast Growth Factor-Induced Angiogenesis”, J. Clin. Invest., vol. 99, No. 11, pp. 2625-2634 (1997).Applicant
• Zwart, D., “Treatment of Grade II Astrocytoma with Thalidomide”, Arzneim.-Forsch., vol. 16, No. 12, pp. 1688-1689 (1966).Applicant
• Braun, A.G. et al., “Teratogen Metabolism,” Energy Research Abstracts, U.S. Department of Energy, Technical Information Center Office of Scientific & Technical Information, (1984) 9(8):5508:15072.Applicant
• Braun, A.G. et al., “Teratogen Metabolism: Activation of Thalidomide and Thalidomide Analogues to Products that Inhibit the Attachment of Cells to Concanavalin A Coated Plastic Surfaces,” Energy Research Abstracts, U.S. Department of Energy, Technical Information Center Office of Scientific & Technical Information, (1984) 9(8):5508:15071.Applicant
• Braun, A.G. et al., “Teratogen Metabolism : Activation of Thalidomide and Thalidomide Analogues to Products that Inhibit the Attachment of Cells to Concanavalin a Coated Plastic Surfaces,” Biochemical Pharmacology (1984) 33(9):1471-1477.Applicant
• Braun, A.G. et al., “Teratogen Metabolism : Activation of Thalidomide and Thalidomide Analogues to Products that Inhibit the Attachment of Cells to Concanavalin a Coated Plastic Surfaces,” Revised Version, U.S. Department of Commerce, National Technical Information Services, Harvard Medical School: Boston, MA (1982) DE84006118.Applicant
• Gordon, G. “Mutagenic and Cytotoxic Studies with Thalidomide,” (unpublished Ph.D. dissertation, The John Hopkins U. 1981) (microformed on UMI Dissertation Abstracts database 8120023).Applicant
• Gordon, G.B. et al., “Thalidomide Teratogenesis: Evidence for a Toxic Arene Oxide Metabolite,” Federation of American Societies for Experimental Biology Federation Proceedings (1981) 40(3): 2508.Applicant
• Gordon, G.B. et al., “Thalidomide Teratogenesis: Evidence for a Toxic Arene Oxide Metabolite,” Proc. Natl. Acad. Sci. (1981) 78(4): 2545-2548.Applicant
• Lisek, C.A. “Structural Elucidation of a Hydroxylated Metabolite of Thalidomide: Evidence Supporting an Arene Oxide Intermediate,” (unpublished Ph.D. dissertation, The John Hopkins U. 1985) (microformed on UMI Dissertation Abstracts database 8609337).Applicant